"Designing Growth Strategies is in our DNA"

Immunology Biosimilars Market Size, Share & Industry Analysis, By Drug Class (TNF-alpha Inhibitors, Interleukin Inhibitors, B-cell/Anti-CD20 Therapies, and Anti-IgE Therapies), By Product (Adalimumab, Infliximab, Etanercept, Rituximab, and Ustekinumab Biosimilars), By Indication (Rheumatology, Gastroenterology, Dermatology, and Allergy & Clinical Immunology), By Age Group (Pediatric and Adults), By Route of Administration (Subcutaneous and Intravenous), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, and Retail & Online Pharmacies), and Regional Forecast, 2026-2034

Last Updated: August 13, 2026 | Format: PDF | Report ID: FBI100200

 

  • 2021-2034
  • 2025
  • 2021-2024
  • 190
Download Free Sample

    man icon
    Mail icon
    Mail icon

Get 30-60 hrs Free Customization

Expand Regional and Country Coverage, Segments Analysis, Company Profiles, Competitive Benchmarking, and End-user Insights.

Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann